李珂，1986年生，籍贯河南，肿瘤药理学家，中国医学科学院医药生物技术研究所研究员，博士生导师。2004年考入山东大学药学专业，2008年获得学士学位。2008年在黄金城赌城,澳门黄金城：药物研究所药理学专业攻读硕/博士学位，从事靶向Toll样受体2抑制肿瘤及多肽类药物的筛选研究。2013年进入中国医学科学院医药生物技术研究所工作，主要研究靶向异常蛋白质降解系统清除肿瘤起始细胞。

围绕“靶向蛋白质降解系统清除肿瘤起始细胞”的研究方向：筛选维持肿瘤起始细胞功能的特异性标志分子或关键信号通路；解析维持肿瘤起始细胞功能的靶蛋白稳定性调控机制；对药靶蛋白进行药物设计和筛选。

黄金城赌城,澳门黄金城

1. Li K#*, Zhang TT#, Zhao CX#, Wang F, Cui B, Yang ZN, Lv XX, Yeerjiang Z, Yuan YF, Yu JM, Wang ZH, Zhang XW, Yu JJ, Liu SS, Shang S, Huang B, Hua F*, Hu ZW*. Faciogenital Dysplasia 5 supports cancer stem cell traits in basal-like breast cancer by enhancing EGFR stability. Sci Transl Med 2021 Mar 24;13(586): eabb2914. （IF=19.351）

2. Li K#, Wang F#, Yang ZN, Zhang TT, Yuan YF, Zhao CX, Y Z, Cui B, Hua F, Lv XX, Zhang XW, Yu JJ, Liu SS, Yu JM, Shang S, Xiao Y, Hu ZW*. TRIB3 Promotes MYC-associated Lymphoma Development through Suppression of UBE3B-Mediated MYC Degradation. Nat Commun. 2020 11(1): 6316. （IF=14.919）

3. Li K#, Wang F#, Yang ZN#, Cui B, Li PP, Li ZY, Hu ZW*, Zhu HH*. PML-RARα interaction with TRIB3 impedes PPARγ/RXR function and triggers dyslipidemia in acute promyelocytic leukemia. Theranostics. 2020 Aug 15;10(22): 10326-10340. (IF=11.556)

4. Zhu HH#, Yang MC#, Wang F#, Lou YJ, Jin J, Li K*, Zhang SZ*. Identification of a novel NUP98-RARA fusion transcript as the 14th variant of acute promyelocytic leukemia. Am J Hematol. 2020 Jul;95(7): E184-E186. (IF=10.047)

5. Xue ST#, Li K#, Gao Y, Zhao LY, Gao Y, Yi H, Jiang JD*, and Li ZR*. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target. Autophagy, 2020 Jan 27: 1-15. (IF=16.016)

6. Li K, Zhang TT, Hu ZW*. Metformin Reduces TRIB3 Expression and Restores Autophagy Flux: An Alternative Antitumor Action. Autophagy. 2018 Jul 20: 1-2. (IF=11.059)

7. Li K, Zhang TT, Wang F, Cui B, Zhao CX, Yu JJ, Lv XX, Zhang XW, Yang ZN, Huang B, Li X, Hua F, Hu ZW*. Metformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expression. Oncogene. 2018 Jul 20: 1-2. (IF=6.854)

8. Li K#, Wang F#, Cao WB, Lv XX, Hua F, Cui B, Yu JJ, Zhang XW, Shang S, Liu SS, Yu JM, Han MZ, Huang B, Zhang TT, Li X, Jiang JD, Hu ZW*. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARa and Inhibition of p53-Mediated Senescence. Cancer Cell, 2017, 31: 697-710. (IF=22.844)

9. Hua F#, Li K#, Yu JJ#, Lv XX, Yan J, Zhang XW, Sun W, Lin H, Shang S, Wang F, Cui B, Mu R, Huang B, Jiang JD, Hu ZW*. TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations. Nat Commun. 2015, 13;6: 7951. (#contributing equally) (IF=11.329)

10. Li K#, Lv XX, Hua F, Lin H, Sun W, Cao WB, Fu XM, Xie J, Yu JJ, Li Z, Liu H, Han MZ and Hu ZW*. Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a Toll-like receptor 2-mediated cell-penetrating peptide. Intl J Cancer. 2014; 134: 692-702. (IF=5.085)